BioLineRx Ltd.
BLRX
$3.61
-$0.24-6.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.03% | 93.09% | 84.79% | 62.03% | 30.42% |
| Total Depreciation and Amortization | 32.08% | 66.07% | 201.28% | 230.64% | 181.18% |
| Total Amortization of Deferred Charges | 105.99% | 3,435.59% | 2,245.76% | -- | 309.94% |
| Total Other Non-Cash Items | -1,328.38% | -259.38% | -185.00% | -143.56% | -110.03% |
| Change in Net Operating Assets | -18.43% | -378.18% | -243.55% | -481.66% | -394.12% |
| Cash from Operations | 30.13% | -12.73% | -94.06% | 9.04% | 5.35% |
| Capital Expenditure | 107.89% | 81.90% | 54.31% | 52.23% | 54.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 215.33% | -60.96% | 1,786.35% | -108.13% | -219.64% |
| Cash from Investing | 214.47% | -60.75% | 1,934.21% | -108.47% | -223.80% |
| Total Debt Issued | -100.00% | -- | -- | 3,557.37% | 110.64% |
| Total Debt Repaid | -333.56% | -439.96% | -651.71% | -203.86% | -170.26% |
| Issuance of Common Stock | 8.58% | 59.92% | -2.85% | 308.82% | 60.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -77.17% | 118.15% | 37.21% | 1,155.41% | 74.64% |
| Foreign Exchange rate Adjustments | 687.13% | -48.00% | 109.82% | 111.16% | 74.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -406.03% | 199.02% | 197.62% | 120.62% | 87.65% |